Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

A study has found that taking Femara for 10 years instead of 5 reduces the risk of recurrence of a new breast cancer being diagnosed in the contralateral breast.

 New England Journal of Medicine

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.